It was announced today that Irish biotechnology and R&D company, Nuritas, has received over €3 million from the Horizon 2020 fund to support the final stage of its research and the commercialisation of what would be a world-first development in diabetes prevention.
This will include a series of Irish-based clinical trials being rolled out over the next 18 months. Pending regulatory approval, Nuritas will have its new peptide integrated into functional food products and available on the market as early as 2020.
The significance of the Nuritas breakthrough has also been hailed internationally in the medical community as there have been few advances made in preventative solutions aimed at pre-diabetic patients.
The World Health Organisation has declared diabetes to be a global epidemic affecting 422 million people, with 1.5 million dying in 2012 alone. Nine out of 10 sufferers have Type 2 diabetes and a staggering 1 in every 3 adults over 30 in England are now classed as pre-diabetic.
Commenting today, Nuritas CEO, Emmet Browne said, "This is a hugely important validation for Nuritas and our use of cutting-edge artificial intelligence driven technology to transform the future of disease prevention and food around the globe. While we have a rich pipeline of similar breakthrough peptides, all found from natural sources with amazing scientific potential, diabetes prevention now becomes Nuritas’ first important area of focus, with many more to follow."
Source: www.businessworld.ie